Solid Biosciences Inc. - Common Stock (SLDB)
Frequently Asked Questions About Solid Biosciences Inc. - Common Stock (SLDB)
Has SGT-001 been tested in clinical trials?
Yes, SGT-001 has been evaluated in clinical trials, specifically in Phase I/II studies. Early results have focused on safety and the potential efficacy of the therapy in patients with DMD, which is crucial for determining further development.
Has Solid Biosciences received any awards or recognitions?
Solid Biosciences has received various recognitions and awards within the biotechnology community for its innovative approach to gene therapy and commitment to addressing unmet medical needs in muscle diseases. These accolades reflect the company’s dedication to advancing solutions for patients.
How can stakeholders stay informed about Solid Biosciences?
Stakeholders can stay informed about Solid Biosciences through the company’s official website, press releases, social media channels, and by reviewing its filings with the U.S. Securities and Exchange Commission (SEC). Regular updates provide insights into company developments and progress.
How does Solid Biosciences ensure compliance with regulations?
Solid Biosciences follows strict regulatory guidelines established by the U.S. Food and Drug Administration (FDA) and other governing bodies. The company implements rigorous protocols for clinical trials and product development to maintain compliance and ensure patient safety.
How does Solid Biosciences fund its research and development?
Solid Biosciences funds its research and development activities through a combination of equity financing, grants, partnerships, and potentially through collaborations with larger pharmaceutical companies aimed at gene therapy advancements.
How is SGT-001 delivered?
SGT-001 is delivered via an adeno-associated virus (AAV) vector, which is engineered to carry the therapeutic gene into the muscle cells. This method aims to facilitate the uptake of the gene and promote its expression to produce the dystrophin protein.
What challenges does Solid Biosciences face?
Like many biotechnology companies, Solid Biosciences faces challenges such as regulatory hurdles, competition from other therapies, financing for ongoing development, and the complex nature of successfully developing and commercializing gene therapies.
What does Solid Biosciences Inc. do?
Solid Biosciences Inc. is a biotechnology company focused on developing gene therapies for muscle diseases, particularly Duchenne Muscular Dystrophy (DMD). The company's mission is to address the urgent needs of patients through innovative therapies that aim to restore muscle health and function.
What financial information is available for Solid Biosciences?
As a publicly traded company on the Nasdaq under the ticker SLDB, Solid Biosciences provides financial reports and disclosures in accordance with U.S. Securities and Exchange Commission (SEC) regulations. This information includes quarterly earnings, financial health, and other relevant data for investors.
What is Duchenne Muscular Dystrophy (DMD)?
Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness due to the absence of dystrophin, a protein essential for muscle health. DMD primarily affects boys and can lead to significant disability and reduced quality of life.
What is Solid's lead product candidate?
Solid Biosciences' lead product candidate is SGT-001, a gene therapy designed to deliver a copy of the dystrophin gene to muscle cells. The goal is to enable these cells to produce dystrophin, thereby improving muscle function in patients with DMD.
What is the company's approach to patient engagement?
Solid Biosciences places high importance on patient engagement, actively involving patients, caregivers, and advocacy groups in the development process. The company seeks to understand the needs and experiences of the DMD community to better tailor its research and programs.
What is the corporate governance structure of Solid Biosciences?
Solid Biosciences has a board of directors comprising experienced professionals from various fields, including biotechnology, finance, and academia. This diverse governance structure aims to provide effective oversight and strategic direction for the company.
What is the current stage of development for SGT-001?
As of the latest updates, SGT-001 is in clinical development, with ongoing trials aimed at gathering more data on its safety, efficacy, and optimal dosing in patients with Duchenne Muscular Dystrophy. The company continues to work towards advancing the therapy through the regulatory process.
What other programs does Solid Biosciences have?
In addition to SGT-001, Solid Biosciences is exploring other programs focused on different aspects of muscle health and gene therapy. These may include additional gene therapies or technologies aimed at enhancing the treatment landscape for individuals suffering from muscular diseases.
When was Solid Biosciences Inc. founded?
Solid Biosciences Inc. was founded in 2013. The company started with the goal of advancing genetic medicine and specifically targeting muscle diseases, leveraging research and advancements in gene therapy.
Where is Solid Biosciences Inc. headquartered?
Solid Biosciences Inc. is headquartered in Cambridge, Massachusetts, a hub for biotechnology and pharmaceutical research, providing access to a rich ecosystem of scientific talent and collaborations.
Who are Solid Biosciences' collaborators?
Solid Biosciences collaborates with various academic institutions, research organizations, and industry partners to advance its research and development efforts. These collaborations are vital for leveraging expertise and resources in the field of gene therapy and muscular disorders.
What is the current price of Solid Biosciences Inc. - Common Stock?
The current price of Solid Biosciences Inc. - Common Stock is 3.090
When was Solid Biosciences Inc. - Common Stock last traded?
The last trade of Solid Biosciences Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Solid Biosciences Inc. - Common Stock?
The market capitalization of Solid Biosciences Inc. - Common Stock is 60.57M
How many shares of Solid Biosciences Inc. - Common Stock are outstanding?
Solid Biosciences Inc. - Common Stock has 19.60M shares outstanding.